Loading...
Hikma Pharmaceuticals Community
LSE:HIK Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 39 Fair Values set on narratives written by author
Community Investing Ideas
Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds
Key Takeaways Expanding global manufacturing and focus on complex generics position Hikma to benefit from rising pharmaceutical demand and the shift toward more cost-effective health solutions. Robust R&D, resilient MENA operations, and strong supply chain compliance provide higher-margin growth, stable performance amid regional volatility, and greater reliability than import-dependent peers.Read more
1users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
UK£23.55
32.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
6.21% p.a.
Profit Margin
15.38%
Future PE
14.34x
Share price in 2028
UK£28.84